Dyslipidemia denials in California external review

What the reviewers wrote

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. The submitted documentation supports the medical necessity of the requested medication. The U.S. Food and Drug Administration (FDA) approves the use of Zepbound (tirzepatide) injection for chronic weight management in adults with obesity, defined as a BMI of 30 kg/m² or greater, or who are overweight, defined as a BMI of 27 kg/m² or greater, with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol for use in addition to a reduced calorie diet and increased physical activity. Anti-obesity medications, when combined with lifestyle intervention, produce larger weight losses than behavioral treatment alone.

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement and prospective authorization and coverage for Zepbound. The submitted documentation supports the medical necessity of the requested medication. The U.S. Food and Drug Administration (FDA) approves the use of Zepbound (tirzepatide) injection for chronic weight management in adults with obesity, defined as a BMI of 30 kg/m² or greater, or who are overweight, defined as a body mass index (BMI) of 27 kg/m² or greater, with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol for use in addition to a reduced calorie diet and increased physical activity. Anti-obesity medications, when combined with lifestyle intervention, produce larger weight losses than behavioral treatment alone.

Where the denial was upheld

Physician 1: The patient is a 50-year-old female with a history of hyperlipidemia and low levels of HDL treated with gemfibrozil and Pravachol. She had a baseline EBCT in 2003 and a second imaging study in June 2005. The Health Plan denied the patient’s request for reimbursement of the follow-up study based upon their determination that EBCT is considered experimental/ investigational for evaluation of coronary artery disease. In adults at low risk for coronary heart disease (CHD) events, the United States Preventive Services Task Force (USPSTF) now recommends against routine screening for either the presence of severe coronary artery stenosis (CAS) or the prediction of CHD events with resting electrocardiography (ECG), exercise treadmill test (ETT), or electron-beam computed tomography (EBCT) scanning for coronary calcium.

Nature of Statutory Criteria/Case Summary: The patient presented for a cardiovascular risk assessment evaluation secondary to a diagnosis of dyslipidemia. The most recent cholesterol level is 209, with low density lipoprotein (LDL) of 114 and high density lipoprotein (HDL) of 78. The patient denied associated symptoms, including decreased activity or exercise tolerance, shortness of breath, swelling, or chest pain. There was no documented history of hypertension or diabetes. The patient was educated and following a low carbohydrate, low fat diet, and exercising five to six times per week. She was referred for advanced lipoprotein testing including lipid particle number and sizing for further risk stratification.

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving dyslipidemia, then check the rights and deadlines that apply to your plan.